BioXcel Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Steinhart Richard I | Chief Financial Officer | Option Exercise | 521 | — | — | 5,286 | Jun 15, 2024 |
| Mehta Vimal | CEO and President | Option Exercise | 2,609 | — | — | 46,173 | Jun 15, 2024 |
| Yocca Frank | Chief Scientific Officer | Sale | 372 | $1.28 | $476 | 13,474 | Jun 14, 2024 |
| Rodriguez Javier | See Remarks | Option Exercise | 562 | — | — | 8,755 | Jun 14, 2024 |
| O'Neill Vincent | See Remarks | Sale | 155 | $1.29 | $200 | 3,524 | Jun 14, 2024 |
| BioXcel Holdings, Inc. | — | Sale | 283,122 | — | — | — | Jun 5, 2024 |
| Steinhart Richard I | Chief Financial Officer | Option Exercise | 2,250 | — | — | 5,834 | Apr 4, 2024 |
| Rodriguez Javier | See Remarks | Option Exercise | 2,250 | — | — | 8,684 | Apr 4, 2024 |
| Mehta Vimal | CEO and President | Option Exercise | 2,610 | — | — | 34,832 | Mar 15, 2024 |
| Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | Sale | 1,008 | $2.64 | $2,661 | 2,992 | Mar 15, 2024 |
| O'Neill Vincent | See Remarks | Option Exercise | 2,250 | — | — | 5,573 | Mar 14, 2024 |
| Yocca Frank | Chief Scientific Officer | Option Exercise | 2,250 | — | — | 13,830 | Mar 14, 2024 |
| Yocca Frank | Chief Scientific Officer | Option Exercise | 521 | — | — | 11,059 | Dec 14, 2023 |
| Mehta Vimal | CEO and President | Option Exercise | 2,609 | — | — | 32,222 | Dec 14, 2023 |
| Rodriguez Javier | See Remarks | Option Exercise | 521 | — | — | 5,913 | Dec 14, 2023 |
| Steinhart Richard I | Chief Financial Officer | Option Exercise | 521 | — | — | 3,063 | Dec 14, 2023 |
| O'Neill Vincent | Chief Medical Officer | Option Exercise | 521 | — | — | 2,802 | Dec 14, 2023 |
| Yocca Frank | Chief Scientific Officer | Option Exercise | 521 | — | — | 10,538 | Sep 14, 2023 |
| Steinhart Richard I | Chief Financial Officer | Option Exercise | 521 | — | — | 2,542 | Sep 14, 2023 |
| Rodriguez Javier | See Remarks | Option Exercise | 521 | — | — | 5,392 | Sep 14, 2023 |
| O'Neill Vincent | Chief Medical Officer | Option Exercise | 521 | — | — | 2,281 | Sep 14, 2023 |
| Mehta Vimal | CEO and President | Option Exercise | 2,610 | — | — | 29,613 | Sep 14, 2023 |
| Rodriguez Javier | See Remarks | Option Exercise | 521 | — | — | 4,871 | Jun 14, 2023 |
| Yocca Frank | Chief Scientific Officer | Option Exercise | 521 | — | — | 10,017 | Jun 14, 2023 |
| Steinhart Richard I | Chief Financial Officer | Option Exercise | 521 | — | — | 2,021 | Jun 14, 2023 |
| Mehta Vimal | CEO and President | Sale | 747 | $21.89 | $16,352 | 39,903 | Jun 14, 2023 |
| O'Neill Vincent | Chief Medical Officer | Option Exercise | 521 | — | — | 1,760 | Jun 14, 2023 |
| Mehta Vimal | CEO and President | Sale | 6,500 | $25.79 | $167,635 | 37,294 | May 22, 2023 |
| Steinhart Richard I | Chief Financial Officer | Option Exercise | 5,000 | — | — | 6,500 | May 15, 2023 |
| Mehta Vimal | CEO and President | Option Exercise | 15,000 | — | — | 30,894 | May 14, 2023 |
| Rodriguez Javier | See Remarks | Sale | 1,785 | $27.32 | $48,766 | 4,350 | May 14, 2023 |
| Nandabalan Krishnan | — | Sale | 60,000 | $17.32 | $1,039,200 | — | Apr 6, 2023 |
| Mehta Vimal | CEO and President | Sale | 604 | $18.88 | $11,404 | 15,894 | Mar 20, 2023 |
| Steinhart Richard I | Chief Financial Officer | Sale | 2,084 | $19.50 | $40,638 | 1,500 | Mar 14, 2023 |
| Yocca Frank | Chief Scientific Officer | Sale | 985 | $19.69 | $19,395 | 9,496 | Mar 14, 2023 |
| Mehta Vimal | CEO and President | Option Exercise | 10,437 | — | — | 20,394 | Mar 14, 2023 |
| O'Neill Vincent | Chief Medical Officer | Sale | 845 | $19.70 | $16,647 | 1,239 | Mar 14, 2023 |
| Rodriguez Javier | See Remarks | Sale | 950 | $19.63 | $18,649 | 1,135 | Mar 14, 2023 |
| Yocca Frank | Chief Scientific Officer | Sale | 50,000 | $30.00 | $1,500,000 | 8,397 | Jan 20, 2023 |
| O'Neill Vincent | Chief Medical Officer | Option Exercise | 29,713 | $0.41 | $12,182 | 29,713 | Jan 20, 2023 |
| Nandabalan Krishnan | — | Sale | 9,821 | $22.21 | $218,124 | — | Jan 5, 2023 |
| Mehta Vimal | CEO and President | Sale | 7,206 | $20.19 | $145,489 | 9,957 | Dec 15, 2022 |
| Nandabalan Krishnan | — | Gift | 145,549 | — | — | 8,546,750 | Nov 15, 2022 |
| Mehta Vimal | CEO and President | Gift | 145,549 | — | — | 8,546,750 | Nov 15, 2022 |
| Nandabalan Krishnan | — | Sale | 32,550 | $15.00 | $488,250 | — | Nov 10, 2022 |
| Mehta Vimal | CEO, President and Secretary | Sale | 473,250 | $30.83 | $14,590,298 | 8,546,750 | Jun 25, 2021 |
| Nandabalan Krishnan | — | Sale | 473,250 | $30.83 | $14,590,298 | 8,546,750 | Jun 25, 2021 |
| BioXcel LLC | — | Sale | 473,250 | $30.83 | $14,590,298 | 8,546,750 | Jun 25, 2021 |
| BioXcel Holdings, Inc. | — | Sale | 473,250 | $30.83 | $14,590,298 | 8,546,750 | Jun 25, 2021 |
| Mehta Vimal | CEO and President | Gift | 130,659 | — | — | 8,546,750 | Apr 6, 2021 |